Protective effect of cysteinyl leukotriene receptor antagonist montelukast  in bleomycin-induced pulmonary fibrosis

Topaloğlu, Nurhayat; Yıldızeli, Şehnaz Olgun; Şener, Göksel; Laçin, Tunç; Şehirli, Özer; Bozkurtlar, Emine; Çelikel, Çiğdem; Ceyhan, Berrin

doi:10.5606/tgkdc.dergisi.2019.15149

Cited by 13 publications

(10 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…LTE4, which is one of the CysLTs, is the form that is more stable and abundant in biological fluids compared with others. CysLTs is known to play an important role in inflammatory diseases of the respiratory tract, such as asthma [15] pulmonary inflammation and fibrosis [16] and acute respiratory distress syndrome (ARDS) [17][18][19].…”

Section: Introductionmentioning

confidence: 99%

The assessment of the serum levels of TWEAK and prostaglandin F2α in COVID – 19

et al. 2020

View full text Add to dashboard Cite

Background/aim: It is claimed that aberrant immune response has a more important role than the cytopathic effect of the virus in the morbidity and mortality of the coronavirus disease 2019 (COVID-19). We aimed to investigate the possible roles of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) / Fn14 pathway and leukotrienes (LT) in uncontrolled immune response that occurs in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Materials and methods: This study included 25 asymptomatic patients and 35 patients with lung involvement who were diagnosed with COVID-19 as well as 22 healthy volunteer. Lung involvement was determined using computed-tomography. Serum TWEAK, LTE4, and prostaglandin F2α (PGF2α) levels were determined. Results: Compared with the healthy control group, TWEAK, LTE4, and PGF2α levels were higher in the group of SARS-CoV-2 infection without lung involvement. In the group of SARS-CoV-2 infection with lung involvement, age, fibrinogen, sedimentation, C-reactive protein and ferritin, TWEAK, LTE4, and PGF2α levels were higher, and lymphocyte levels were lower compared with the asymptomatic group. Conclusions: In the study, TWEAK and LTE4 levels increased in cases with COVID-19. These results support that TWEAK / Fn14 pathway and LT may involved in the pathology of aberrant immune response against SARS-CoV-2. Inhibition of each of these pathways may be a potential target in the treatment of COVID-19.

show abstract

Section: Introductionmentioning

confidence: 99%

The assessment of the serum levels of TWEAK and prostaglandin F2α in COVID – 19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…MK regulates the extracellular remodeling matrix and inhibits the formation of fibrosis (Debelleix et al, 2018). This anti-fibrotic potential has been confirmed in an animal model of pulmonary fibrosis induced by bleomycin (Topaloglu et al, 2018). Similarly, a recent meta-analysis confirmed in women that MK decreases the risk of retractile fibrosis after the placement of a silicone implant in breast reconstruction surgery (Wang et al, 2020).…”

Section: Anti-fibrosis Propertiesmentioning

confidence: 86%

Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence

Barre¹,

Sabatier

Annweiler

2020

Front. Pharmacol.

View full text Add to dashboard Cite

With the lack of effective therapy, chemoprevention and vaccination, focusing on the immediate repurposing of existing drugs gives hope of curbing the pandemic. Interestingly, montelukast, a drug usually used in asthma, may be proposed as a potential adjuvant therapy in COVID-19. The aim of the present article was to review the properties of montelukast that could be beneficial in COVID-19. Ten experimentally supported properties were retrieved, either related to SARS-CoV-2 (antiviral properties, prevention of endotheliitis and of neurological disorders linked to SARS-CoV-2), and/or related to the host (improvement of atherogenic vascular inflammation, limitation of the ischemia/reperfusion phenomenon, improvement of respiratory symptoms), and/or related to serious COVID-19 outcomes (limitation of the cytokine storm, mitigation of acute respiratory distress syndrome), and/or related to tissue sequelae (antioxidant properties, anti-fibrosis effects). Based on gathered theoretical evidence, we argue that montelukast should be further tested to prevent and treat COVID-19 outcomes.

show abstract

“…LTs have been extensively studied in IPF and in their animal model, bleomicyn-induced pulmonary fibrosis mice. In this model, an important role of LTB4 and CysLT through BLT1 and CysLT 2 receptors [13,16] in fibrosis induction has been showed, and deletion [16,17] or blocking of LTs receptors [18] or their biosynthetic enzymes, including 5-LO, LTC4 synthase [16,19], and LTA4 hydrolase [12], were related with a significant reduction of fibrosis. Evidence supports that LTs induce fibrosis by inducing transforming growth factor beta (TGF-β) release from macrophages and epithelial cells [8,17,20].…”

Section: Introductionmentioning

confidence: 82%

Systemic Sclerosis: Elevated Levels of Leukotrienes in Saliva and Plasma Are Associated with Vascular Manifestations and Nailfold Capillaroscopic Abnormalities

Mandujano

Méndez-Ramı́rez

Silveira-Torre

2021

IJERPH

View full text Add to dashboard Cite

The role of leukotrienes (LTs) in the pathogenesis of systemic sclerosis (SSc) needs clarification. We analyzed the association of salivary (sa) and plasma (p) levels (pg/mL) of cysteinyl-leukotrienes (CysLT) and LTB4 with SSc vascular manifestations and nailfold capillaroscopy (NFC) in a cross-sectional study. Patients and healthy controls were evaluated for vascular manifestations and NFC. LTs were compared between groups as follows: SSc with or SSc without vascular features and controls, and by NFC parameters. Twenty SSc patients and 16 volunteers were recruited; Raynaud’s phenomenon (RP) history (SSc: saCysLT 99.4 ± 21.8 vs. controls: 23.05 ± 23.7, p = 0.01), RP at examination (SSc: saCysLT 129.3 ± 24.6 vs. controls: 23.05 ± 22.46, p = 0.01; pCysLT SSc: 87.5 ± 11.2 vs. controls: 32.37 ± 10.75, p = 0.002), capillary loss (saCysLT 138.6 ± 26.7 vs. 23.05 ± 21.6, p = 0.0007; saLTB4 3380.9 ± 426.6 vs. 1216.33 ± 346.1, p = 0.0005), “late” scleroderma pattern vs. controls (saCysLT 205.6 ± 32 vs. 23 ± 19.6, p = 0.0002; saLTB4 4564.9 ± 503.6 vs. 1216.3 ± 308.3; p < 0.0001) were all significant. Late patterns had higher levels (saCysLT, p = 0.002; LTB4 p = 0.0006) compared to active and early patterns (LTB4, p = 0.0006), and giant capillaries (p = 0.01) showed higher levels of LTs. Levels of pCysLT were higher in patients with RP at examination vs. patients without RP; saCysLT and LTB4 were higher in SSc group with vs. without capillary loss. LTs could be involved in the pathophysiology of vascular abnormalities. Further research is required to determine if blocking LTs could be a therapeutic target for SSc vascular manifestations.

show abstract

Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin-induced pulmonary fibrosis

Cited by 13 publications

References 44 publications

The assessment of the serum levels of TWEAK and prostaglandin F2α in COVID – 19

The assessment of the serum levels of TWEAK and prostaglandin F2α in COVID – 19

Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence

Systemic Sclerosis: Elevated Levels of Leukotrienes in Saliva and Plasma Are Associated with Vascular Manifestations and Nailfold Capillaroscopic Abnormalities

Contact Info

Product

Resources

About